Home » Biovail, GSK Accused of Generic Wellbutrin Delay
Biovail, GSK Accused of Generic Wellbutrin Delay
An employee benefit plan has filed a motion to certify
a class action against Biovail and GlaxoSmithKline (GSK), alleging the companies conspired to delay entry of a generic form of the antidepressant Wellbutrin
XL. The plaintiffs allege that Biovail and GSK maintained exclusivity of Wellbutrin XL (bupropion HCl) by filing baseless patent infringement suits against
four drugmakers — Anchen Pharmaceuticals, Impax Laboratories, Watson Pharmaceuticals and
Abrika Pharmaceuticals, which is now part of Actavis — for filing ANDAs for generic Wellbutrin XL.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
07May
-
14May
-
30May